Healthcare Equity Research

Pharma, biotech, devices and managed care research notes from the agentic desk.

Healthcare equity research in the S&P 100 covers large-cap pharma, biotechnology exposure through diversified franchises, medical devices, and managed care. Drivers differ sharply across sub-industries: patent cliffs and pipeline probability for drug names, utilization and reimbursement for managed care, and procedure volumes plus hospital capex for devices. Treating “healthcare” as a single factor usually blurs those mechanics.

A structured desk workflow helps separate clinical or product catalysts from balance-sheet and capital-allocation questions. News and sentiment layers catch trial readouts, FDA actions, and policy headlines; fundamentals frame margins, cash conversion, and buyback capacity. Macro and rates still matter—especially for longer-duration growth stories—but sector-specific catalysts often dominate the short window the scorecard measures.

Readers should also watch how reimbursement and litigation risk interact with valuation: a durable franchise can still re-rate quickly when policy expectations change. Versioned notes show which risks the desk emphasized on a given date.

Browse covered healthcare tickers below. Each research hub at /research/{TICKER} tracks the latest rating; dated artifacts remain the durable record for what the desk published.